International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.
The Lancet. Oncology.
Times cited: 23
- Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice. American journal of hematology. 2016 Academic Article GET IT
- Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. Leukemia & lymphoma. 2015 Academic Article GET IT
- Conflicts of interest, authorship, and disclosures in industry-related scientific publications. Mayo Clinic proceedings. 2010 Information Resource GET IT
- Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood. 2009 Academic Article GET IT